Noninvasive Respiratory Support Outside the Intensive Care Unit in COVID-19 Pneumonia: a Multicentric Study (CATCOVID-AIR)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 367
- 试验地点
- 10
- 主要终点
- Treatment failure
研究概览
简要总结
COVID-19 pneumonia can cause severe acute hypoxemic respiratory failure. The usefulness of noninvasive respiratory support (NIRS), by means of nasal high-flow oxygen (NHFO), continuous positive airway pressure (CPAP), or noninvasive ventilation (NIV), established outside the intensive care unit, is unknown. The aim of this multicenter, retrospective, longitudinal study is to compare the effectiveness of these treatments to prevent death or endotracheal intubation at day 28, and what factors, related to the disease or to the characteristics of the treatment itself, can condition its success or failure.
详细描述
Multicenter, retrospective, longitudinal study in consecutive adult COVID-19 patients with acute respiratory failure, requiring noninvasive respiratory support (NIRS) outside the intensive care unit (ICU) in 10 hospitals in Catalonia (Spain). Demographic, laboratory, clinical and noninvasive respiratory support data will be collected and analyzed according to the primary outcome (death or endotracheal intubation at day 28) and secondary outcomes (see the dedicated section).
During the hospitalization, patients were treated according to the standard procedures of the participating centers. This study is observational and no randomization have been performed.
Patients were followed up to either 28-days or hospital discharge if still hospitalized at day 28 from NIRS initiation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •COVID-19 pneumonia confirmed with polymerase chain reaction (PCR).
- •Acute respiratory failure.
- •Treated by noninvasive respiratory support (nasal high-flow oxygen, CPAP or noninvasive ventilation), initiated outside the intensive care unit.
- •Age > 18 years
排除标准
- •Acute respiratory failure not related to COVID-19
- •Hypercapnic acute respiratory failure
- •Early intolerance to treatment
- •Nosocomial infection
- •Pregnant woman
结局指标
主要结局
Treatment failure
时间窗: 28 days within noninvasive respiratory support initiation
Death or endotracheal intubation
次要结局
- Duration of hospital stay(Until 28 days from noninvasive respiratory support initiation)
- 28-day mortality(28 days within noninvasive respiratory support initiation)
- Hospital mortality(Until 28 days from noninvasive respiratory support initiation)
- Endotracheal intubation(28 days within noninvasive respiratory support initiation)